Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC8A1 | P32418 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538191 | 0.92 | TNKS (0.41) | TNKSHTR2BPIK3CANPC1RAB9A | |
| SCHEMBL4355595 | 0.89 | POLB (0.54) | POLBTNKSHTR2BSMN1; SMN2CYP2C9 | |
| SCHEMBL4362448 | 0.88 | TNKS (0.44) | TNKSHTR2BPIK3CANPC1RAB9A | |
| SCHEMBL4348683 | 0.87 | TNKS (0.41) | TNKSHTR2BPIK3CANPC1RAB9A | |
| SCHEMBL4355330 | 0.87 | GPR119 (0.39) | TNKSHTR2BPIK3CASLC8A1GSK3B | |
| SCHEMBL4355344 | 0.86 | GPR119 (0.43) | TNKSPTPN2PTPN1 | |
| SCHEMBL4351738 | 0.86 | TNKS (0.38) | TNKSHTR2BPIK3CANPC1RAB9A | |
| SCHEMBL4357683 | 0.84 | POLB (0.48) | POLBTNKSSMN1; SMN2CYP2C9BMPR1B | |
| SCHEMBL4540460 | 0.83 | SMN1; SMN2 (0.43) | HTR2BPIK3CANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4520212 | 0.82 | PTPN2 (0.47) | POLBHTR2BPIK3CASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009150144-A1 | NEW GPR119MODULATORS | INOVACIA AB (SE) | 2009-12-17 | — | — | WO | claimed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2009150144-A1 | NEW GPR119MODULATORS | INOVACIA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150144-A1 | NEW GPR119MODULATORS | INOVACIA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | POLB 2478/4885TNKS 3296/4885HTR2B 1151/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | POLB 2282/4885TNKS 3692/4885HTR2B 1093/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | POLB 2282/4885TNKS 3692/4885HTR2B 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.